Cargando…

Pyridostigmine induced heart block requiring ICU admission

Myasthenia gravis is an autoimmune disorder that effects an estimated 20 people per 100,000 in the USA per year. Pyridostigmine is a common drug used in the symptomatic treatment of myasthenia gravis. While generally safe and effective, a rare set of patients treated with pyridostigmine encounter ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaucer, Benjamin, Whelan, Dustin, Lamichhane, Dronacharya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197028/
https://www.ncbi.nlm.nih.gov/pubmed/30357043
http://dx.doi.org/10.1080/20009666.2018.1527668
_version_ 1783364675493167104
author Chaucer, Benjamin
Whelan, Dustin
Lamichhane, Dronacharya
author_facet Chaucer, Benjamin
Whelan, Dustin
Lamichhane, Dronacharya
author_sort Chaucer, Benjamin
collection PubMed
description Myasthenia gravis is an autoimmune disorder that effects an estimated 20 people per 100,000 in the USA per year. Pyridostigmine is a common drug used in the symptomatic treatment of myasthenia gravis. While generally safe and effective, a rare set of patients treated with pyridostigmine encounter cardiac conduction disorders. Here, we report a rare presentation of an adverse drug reaction due to pyridostigmine, which is important for its implications in the acute care setting.
format Online
Article
Text
id pubmed-6197028
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61970282018-10-23 Pyridostigmine induced heart block requiring ICU admission Chaucer, Benjamin Whelan, Dustin Lamichhane, Dronacharya J Community Hosp Intern Med Perspect Case Report Myasthenia gravis is an autoimmune disorder that effects an estimated 20 people per 100,000 in the USA per year. Pyridostigmine is a common drug used in the symptomatic treatment of myasthenia gravis. While generally safe and effective, a rare set of patients treated with pyridostigmine encounter cardiac conduction disorders. Here, we report a rare presentation of an adverse drug reaction due to pyridostigmine, which is important for its implications in the acute care setting. Taylor & Francis 2018-10-15 /pmc/articles/PMC6197028/ /pubmed/30357043 http://dx.doi.org/10.1080/20009666.2018.1527668 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Chaucer, Benjamin
Whelan, Dustin
Lamichhane, Dronacharya
Pyridostigmine induced heart block requiring ICU admission
title Pyridostigmine induced heart block requiring ICU admission
title_full Pyridostigmine induced heart block requiring ICU admission
title_fullStr Pyridostigmine induced heart block requiring ICU admission
title_full_unstemmed Pyridostigmine induced heart block requiring ICU admission
title_short Pyridostigmine induced heart block requiring ICU admission
title_sort pyridostigmine induced heart block requiring icu admission
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197028/
https://www.ncbi.nlm.nih.gov/pubmed/30357043
http://dx.doi.org/10.1080/20009666.2018.1527668
work_keys_str_mv AT chaucerbenjamin pyridostigmineinducedheartblockrequiringicuadmission
AT whelandustin pyridostigmineinducedheartblockrequiringicuadmission
AT lamichhanedronacharya pyridostigmineinducedheartblockrequiringicuadmission